- Trials with a EudraCT protocol (144)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
144 result(s) found for: Sitagliptin.
Displaying page 1 of 8.
EudraCT Number: 2014-004993-40 | Sponsor Protocol Number: MK-0431-081 | Start Date*: 2015-04-01 |
Sponsor Name:Merck & Co., Inc. | ||
Full Title: A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Sitagliptin in Adolescents | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-002685-70 | Sponsor Protocol Number: 300A | Start Date*: 2015-08-03 |
Sponsor Name:Lund University | ||
Full Title: The Effect of Sitagliptin on Glucagon Dynamics and Incretin Hormones During Mild Hypoglycemia in Elderly Patients with Metformin-Treated Type 2 Diabetes | ||
Medical condition: Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003698-82 | Sponsor Protocol Number: MK8835-005 | Start Date*: 2014-07-09 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin A... | |||||||||||||
Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) IT (Completed) GB (Completed) FI (Completed) SK (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004224-59 | Sponsor Protocol Number: MK-0431-848 | Start Date*: 2016-07-27 |
Sponsor Name:Merck Sharp & Dohme Corp. | ||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared with Met... | ||
Medical condition: Type 2 Diabetes mellitus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-003731-22 | Sponsor Protocol Number: MK-0431A-296 | Start Date*: 2020-09-03 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Study to Assess the Pharmacokinetics and Ability for Pediatric Patients with Type 2 Diabetes to Swallow MK-0431A XR Tablets | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001120-54 | Sponsor Protocol Number: SQ167015 | Start Date*: 2016-07-25 |
Sponsor Name:University Hospitals Coventry and Warwickshire NHS Trust | ||
Full Title: Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage? | ||
Medical condition: Recurrent miscarriage | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-002607-12 | Sponsor Protocol Number: JVSRS08 | Start Date*: 2008-08-08 |
Sponsor Name:Central Manchester& Manchester Children's University Hospitals NHS Trust | ||
Full Title: Sitagliptin vs sulphonylurea based treatments in Muslim patients with Type 2 diabetes during Ramadan | ||
Medical condition: Muslim patients with type 2 diabets fasting during Ramadan | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-005226-19 | Sponsor Protocol Number: SitaDFU_v1.0 | Start Date*: 2016-07-19 |
Sponsor Name:Medical University of Innsbruck | ||
Full Title: Accelerated wound healing in diabetic ulcers by Sitagliptin | ||
Medical condition: diabetic foot ulcer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005660-98 | Sponsor Protocol Number: 2012-005660-98 | Start Date*: 2013-04-29 |
Sponsor Name:Lund University | ||
Full Title: Effect of a single oral dose DPP-4 inhibitor sitagliptin on islet function after intake of a standardized mixed meal in patients with type 2 diabetes | ||
Medical condition: Type 2 diabetes mellitus. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006719-20 | Sponsor Protocol Number: 0431-082 | Start Date*: 2009-05-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. | |||||||||||||
Full Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control | |||||||||||||
Medical condition: Type 2 diabetes mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) NL (Completed) DE (Completed) ES (Completed) HU (Completed) LV (Completed) FR (Completed) CZ (Completed) GB (Completed) IE (Prematurely Ended) SK (Completed) BG (Completed) IT (Completed) EE (Completed) FI (Completed) SE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005525-13 | Sponsor Protocol Number: MK-0431-838 | Start Date*: 2015-09-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared with the Addition of Dapagli... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) FI (Completed) IE (Completed) EE (Completed) HU (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003600-20 | Sponsor Protocol Number: MK-0431E-211 | Start Date*: 2012-08-02 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Co... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003532-39 | Sponsor Protocol Number: SitaBAT01 | Start Date*: 2014-11-24 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: The effect of sitagliptin on brown adipose tissue and whole-body metabolism in overweight pre-diabetic men | ||
Medical condition: Obesity, dyslipidemia and impaired glucose tolerance | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-002528-42 | Sponsor Protocol Number: 0431-083 | Start Date*: 2011-12-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. A subsidiary of Merck & Co. Inc | |||||||||||||
Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Placebo- and Metformin-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Me... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) LT (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed) BG (Completed) AT (Completed) DK (Completed) SE (Completed) HU (Completed) PL (Completed) SK (Completed) Outside EU/EEA GR (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006074-28 | Sponsor Protocol Number: 0893-015 | Start Date*: 2008-02-21 | |||||||||||
Sponsor Name:Merck Sharp & Dohme (Sweden) AB | |||||||||||||
Full Title: A Phase IIa, Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0893 in Combination With Sitagliptin or in Combination With Me... | |||||||||||||
Medical condition: Type II Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) ES (Completed) DK (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004990-34 | Sponsor Protocol Number: MK-0431-845 | Start Date*: 2016-05-11 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | ||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared with the Withdrawal of Sitagliptin... | ||
Medical condition: Type 2 Diabetes Mellitus (T2DM) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) HU (Completed) LV (Completed) CZ (Completed) ES (Completed) DK (Completed) RO (Completed) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003583-20 | Sponsor Protocol Number: 0431A-170-03 | Start Date*: 2014-12-30 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc | |||||||||||||
Full Title: A Phase III, Multicenter, Double-Blind, Randomized, Placebo -Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004480-39 | Sponsor Protocol Number: DPP4-Hypo | Start Date*: 2017-12-22 | |||||||||||
Sponsor Name:Profil Institut für Stoffwechselforschung GmbH | |||||||||||||
Full Title: DPP-4 inhibition with sitagliptin and the risk for hypoglycaemia in the fasting state in subjects with type 2 diabetes treated to fasting plasma glucose targets with insulin glargine and metformin | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004622-96 | Sponsor Protocol Number: 0431-260 | Start Date*: 2011-12-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as | |||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabet... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IE (Completed) LT (Completed) DK (Completed) HU (Completed) BE (Completed) GB (Completed) IT (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000859-40 | Sponsor Protocol Number: AIFA-2016-02364864 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:UMBERTO I - POLICLINICO DI ROMA | |||||||||||||
Full Title: A randomized, double blind placebo controlled clinical trial to assess the efficacy and safety of sitagliptin on bone measures in women affected by type 2 diabetes. A gender-oriented approach to ad... | |||||||||||||
Medical condition: Type-2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
